entertainment -WSS

entertainment

author：comprehensive 2025-09-06 03:26:41 - browse：6448

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Dario to buy mental health app maker Twill in cash and stock deal

WSS

Doctors' information doesn't help them choose wisely when sick

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

A disappointing year of Humira biosimilars

A new nitrogen execution bill also undermines medical licensing

focus

entertainment

focus

Jerome Adams on the need for new antivirals for Covid

PhRMA lawsuit over Medicare drug price negotiation tossed

Guidelines to prevent youth baseball injuries need more muscle

The dental labor crisis is a moment of opportunity

In age of alternative facts, a scholarly course on calling out crap

New documents shed light on MD Anderson Cancer Institute feud

Wildfire smoke exposes gaps in outdoor worker protections

Medicare threatens to cut off funding for HCA's Mission hospital

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

focus

R1 RCM gets $5.8 billion buyout offer from private equity firm

He's a Nobel laureate. Critics say he was misleading on Covid

A disappointing year of Humira biosimilars

'Revelatory' study finds a smoking impact that remains after quitting

KalVista pill reduced swelling 'attacks' caused by genetic disease

Gilead might be held responsible for not developing a drug

focus

leisure time

hotspot

knowledge